CA2670405A1 - Combination treatments for alzheimer's disease and related neurodegenerative diseases - Google Patents
Combination treatments for alzheimer's disease and related neurodegenerative diseases Download PDFInfo
- Publication number
- CA2670405A1 CA2670405A1 CA002670405A CA2670405A CA2670405A1 CA 2670405 A1 CA2670405 A1 CA 2670405A1 CA 002670405 A CA002670405 A CA 002670405A CA 2670405 A CA2670405 A CA 2670405A CA 2670405 A1 CA2670405 A1 CA 2670405A1
- Authority
- CA
- Canada
- Prior art keywords
- secretase inhibitor
- cyclohexanehexol
- pharmaceutical composition
- disease
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 8
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 7
- 230000004770 neurodegeneration Effects 0.000 title claims description 6
- 238000011284 combination treatment Methods 0.000 title description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229940121773 Secretase inhibitor Drugs 0.000 claims abstract description 21
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 21
- 229960000367 inositol Drugs 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 238000004220 aggregation Methods 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 230000003941 amyloidogenesis Effects 0.000 claims abstract 10
- 230000007082 Aβ accumulation Effects 0.000 claims abstract 5
- 238000009825 accumulation Methods 0.000 claims abstract 5
- 230000002688 persistence Effects 0.000 claims abstract 5
- 230000004845 protein aggregation Effects 0.000 claims abstract 5
- 230000012846 protein folding Effects 0.000 claims abstract 5
- 230000009286 beneficial effect Effects 0.000 claims abstract 3
- 230000002459 sustained effect Effects 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 10
- 239000002439 beta secretase inhibitor Substances 0.000 claims description 4
- 230000002776 aggregation Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- CDAISMWEOUEBRE-CDRYSYESSA-N scyllo-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-CDRYSYESSA-N 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 6
- -1 cycloalkynyl Chemical group 0.000 claims 6
- 125000002252 acyl group Chemical group 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- FGFCSHCXBYAKOL-UHFFFAOYSA-N cyclohexane-1,1,2,2,3,3-hexol Chemical compound OC1(O)CCCC(O)(O)C1(O)O FGFCSHCXBYAKOL-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000014759 maintenance of location Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 150000003573 thiols Chemical class 0.000 claims 2
- 239000003981 vehicle Substances 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 229910006069 SO3H Inorganic materials 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000003302 alkenyloxy group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 125000003435 aroyl group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 150000001733 carboxylic acid esters Chemical class 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- CDAISMWEOUEBRE-NIPYSYMMSA-N epi-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](O)[C@H]1O CDAISMWEOUEBRE-NIPYSYMMSA-N 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 claims 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 150000003462 sulfoxides Chemical class 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000003977 synaptic function Effects 0.000 claims 1
- 125000005309 thioalkoxy group Chemical group 0.000 claims 1
- 125000004001 thioalkyl group Chemical group 0.000 claims 1
- 125000005000 thioaryl group Chemical group 0.000 claims 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 5
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 4
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 4
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 4
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 1
- 101000579647 Penaeus vannamei Penaeidin-2a Proteins 0.000 description 1
- 102000012412 Presenilin-1 Human genes 0.000 description 1
- 108010036933 Presenilin-1 Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 101150089041 aph-1 gene Proteins 0.000 description 1
- 108091007737 beta-secretases Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003540 gamma secretase inhibitor Substances 0.000 description 1
- 102000038383 gamma-secretases Human genes 0.000 description 1
- 108091007739 gamma-secretases Proteins 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 102000046701 nicastrin Human genes 0.000 description 1
- 108700022821 nicastrin Proteins 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86088406P | 2006-11-24 | 2006-11-24 | |
| US60/860,884 | 2006-11-24 | ||
| PCT/CA2007/002118 WO2008061373A1 (en) | 2006-11-24 | 2007-11-22 | Combination treatments for alzheimer's disease and similar diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2670405A1 true CA2670405A1 (en) | 2008-05-29 |
Family
ID=39429352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002670405A Abandoned CA2670405A1 (en) | 2006-11-24 | 2007-11-22 | Combination treatments for alzheimer's disease and related neurodegenerative diseases |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100292157A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2091566A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010510254A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2670405A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008061373A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| WO2008124931A1 (en) * | 2007-04-12 | 2008-10-23 | Joanne Mclaurin | Use of cyclohexanehexol derivatives in the treatment of amyotrophic lateral sclerosis |
| AT506535B1 (de) * | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| JP6499077B2 (ja) | 2012-10-25 | 2019-04-10 | ザ ジェネラル ホスピタル コーポレイション | アルツハイマー病と関連疾患の治療のための併用療法 |
| US10058530B2 (en) | 2012-10-25 | 2018-08-28 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
| US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| US10188757B2 (en) | 2013-10-22 | 2019-01-29 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| GB201416832D0 (en) * | 2014-09-24 | 2014-11-05 | Glaxosmithkline Plc | Methods of treatment |
| NZ732213A (en) | 2014-10-24 | 2019-02-22 | Landos Biopharma Inc | Lanthionine synthetase c-like 2-based therapeutics |
| PT2017095250B (pt) * | 2015-11-30 | 2021-08-06 | Univ De Coimbra | Peptídeos inibidores da bace1 para o tratamento de doenças neurológicas |
| JP2019524865A (ja) | 2016-08-31 | 2019-09-05 | ザ ジェネラル ホスピタル コーポレイション | 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア |
| JP7202376B2 (ja) | 2017-07-20 | 2023-01-11 | エーゼットセラピーズ， インコーポレイテッド | クロモリンナトリウムおよびイブプロフェンの粉末製剤 |
| US11197891B2 (en) | 2017-11-30 | 2021-12-14 | Landos Biopharma, Inc. | Therapies with lanthionine C-like protein 2 ligands and cells prepared therewith |
| JP2021529771A (ja) | 2018-07-02 | 2021-11-04 | ザ ジェネラル ホスピタル コーポレイション | クロモリンナトリウムおよびα−ラクトースの粉末製剤 |
| MX2021006869A (es) | 2018-12-10 | 2021-07-02 | Massachusetts Gen Hospital | Esteres de cromolin y usos de los mismos. |
| WO2021127472A1 (en) | 2019-12-20 | 2021-06-24 | Landos Biopharma, Inc. | Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same |
| EP4132507A4 (en) | 2020-04-06 | 2024-05-15 | The General Hospital Corporation | METHODS FOR TREATING CORONAVIRUS-INDUCED INFLAMMATORY CONDITIONS |
| KR20250078929A (ko) * | 2022-09-07 | 2025-06-04 | 에어젠 파마 엘티디. | 알츠하이머병 치료를 위한 면역치료법과 사일로이노시톨 병용 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4454151A (en) * | 1982-03-22 | 1984-06-12 | Syntex (U.S.A.) Inc. | Use of pyrrolo pyrroles in treatment of ophthalmic diseases |
| US4515722A (en) * | 1982-03-30 | 1985-05-07 | Merck & Co., Inc. | Phosphatidyl inositol analogs useful as anti-inflammatory/analgesic agents |
| US4474806A (en) * | 1982-05-10 | 1984-10-02 | Merck & Co., Inc. | Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents |
| US4952396A (en) * | 1986-11-19 | 1990-08-28 | Linus Pauling Institute Of Science & Medicine | Method of using phytic acid for inhibiting tumor growth |
| US4847082A (en) * | 1987-01-21 | 1989-07-11 | Robert Sabin | Method of treatment of Alzheimer's disease using phytic acid |
| US4758430A (en) * | 1987-01-21 | 1988-07-19 | Robert Sabin | Method of treatment of Alzheimer's disease using phytic acid |
| SE8904355D0 (sv) * | 1989-12-21 | 1989-12-21 | Perstorp Ab | Medicament |
| US5217959A (en) * | 1990-09-06 | 1993-06-08 | Robert Sabin | Method of treating multiple sclerosis with phytic acid |
| US5112814A (en) * | 1990-10-24 | 1992-05-12 | Robert Sabin | Method of treatment of Parkinson's disease using phytic acid |
| KR0185215B1 (ko) * | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| SE9102068L (sv) * | 1991-07-03 | 1993-01-04 | Perstorp Ab | Derivat av inositol, kompositioner innehaallande dessa samt anvaendning daerav |
| SE469260B (sv) * | 1992-02-25 | 1993-06-14 | Perstorp Ab | En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat |
| NZ314111A (en) * | 1992-10-05 | 1997-08-22 | Virginia Tech Intell Prop | Preparation of d-chiro-inositol by reducing d-chiro-3-inosose |
| US5840294A (en) * | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| US5972328A (en) * | 1993-03-29 | 1999-10-26 | Queen's University At Kingston | Method for treating amyloidosis |
| US5643562A (en) * | 1993-03-29 | 1997-07-01 | Queen's University Of Kingston | Method for treating amyloidosis |
| DK0619369T3 (da) * | 1993-04-05 | 2003-10-06 | Aveve Nv | Phytathydrolyse og enzymsammensætning til hydrolyse af phytat |
| ES2130440T3 (es) * | 1993-08-11 | 1999-07-01 | Hokko Chem Ind Co | Proceso para producir d-(quiro)-inositol. |
| SE502574C2 (sv) * | 1994-01-25 | 1995-11-13 | Perstorp Ab | En farmaceutisk komposition med förbättrad biotillgänglighet hos inositolfosfat |
| US5858326A (en) * | 1995-06-06 | 1999-01-12 | Neurochem, Inc. | Methods of increasing amyloid deposition |
| US5756541A (en) * | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
| US6232486B1 (en) * | 1996-06-11 | 2001-05-15 | Nutrimed Biotech | Molecular probes and modulators for PI-PLC and PI 3-kinase |
| US5977078A (en) * | 1996-09-20 | 1999-11-02 | The Regents Of The Univesity Of California | Inositol polyphosphate derivatives and methods of using same |
| US5880099A (en) * | 1996-09-20 | 1999-03-09 | The Regents Of The University Of California | Inositol polyphosphates and methods of using same |
| US5998485A (en) * | 1997-06-16 | 1999-12-07 | Cedars-Sinai Medical Center | Method for modulating immune response with inositol |
| US6153603A (en) * | 1997-06-27 | 2000-11-28 | Perstorp Ab | Method of treating angiogenesis in tumor tissue |
| US6310073B1 (en) * | 1998-07-28 | 2001-10-30 | Queen's University At Kingston | Methods and compositions to treat glycosaminoglycan-associated molecular interactions |
| US6818430B1 (en) * | 1999-06-07 | 2004-11-16 | Hokko Chemical Industry Co., Ltd. | Process for producing L-epi-2-inosose and novel process for producing epi-inositol |
| US6329256B1 (en) * | 1999-09-24 | 2001-12-11 | Advanced Micro Devices, Inc. | Self-aligned damascene gate formation with low gate resistance |
| NZ518685A (en) * | 1999-10-18 | 2004-04-30 | Muscletech Res And Dev Inc | Whey protein derivatives as food supplements that increase nitric oxide production in the body to enhance muscle size and strength |
| US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| DE10031955A1 (de) * | 2000-06-30 | 2002-01-17 | Deutsches Krebsforsch | Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel |
| CA2437561A1 (en) * | 2001-02-06 | 2002-08-15 | Qlt Inc. | Use of additional photodynamic therapy in the treatment of choroidal neovasculature |
| AU2002236988A1 (en) * | 2001-02-06 | 2002-08-19 | Novartis Ag | Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration |
| US20030181531A1 (en) * | 2003-02-11 | 2003-09-25 | David Sherris | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| WO2003007944A1 (en) * | 2001-07-20 | 2003-01-30 | Qlt, Inc. | Treatment of macular edema with photodynamic therapy |
| US20040058313A1 (en) * | 2002-04-24 | 2004-03-25 | Abreu Marcio Marc | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
| US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| ATE458042T1 (de) * | 2003-10-14 | 2010-03-15 | Hokko Chem Ind Co | Verfahren zur herstellung von scyllo-inositol |
| US20050171112A1 (en) * | 2003-11-03 | 2005-08-04 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| US8193250B2 (en) * | 2004-10-22 | 2012-06-05 | Mount Sinai School Of Medicine | Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system |
| EP2186518A1 (en) * | 2004-11-17 | 2010-05-19 | McLaurin, Joanne | Composition and methods for treatment of disorders of protein aggregation |
| US20090170957A1 (en) * | 2005-10-13 | 2009-07-02 | Antonio Cruz | Scyllo-inositol derivatives and their use in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence |
| CA2579188A1 (en) * | 2006-02-17 | 2007-08-17 | Joanne Mclaurin | Treatment of amyloid-related diseases |
| JP2009529502A (ja) * | 2006-03-09 | 2009-08-20 | ワラタ ファーマシューティカルズ， インコーポレイテッド | タンパク質凝集の障害の処置のためのシクロヘキサン多価アルコール処方物 |
| WO2008034244A1 (en) * | 2006-09-21 | 2008-03-27 | Waratah Pharmaceuticals Inc. | The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases |
-
2007
- 2007-11-22 CA CA002670405A patent/CA2670405A1/en not_active Abandoned
- 2007-11-22 US US12/445,164 patent/US20100292157A1/en not_active Abandoned
- 2007-11-22 JP JP2009537460A patent/JP2010510254A/ja active Pending
- 2007-11-22 WO PCT/CA2007/002118 patent/WO2008061373A1/en not_active Ceased
- 2007-11-22 EP EP07845583A patent/EP2091566A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010510254A (ja) | 2010-04-02 |
| EP2091566A1 (en) | 2009-08-26 |
| WO2008061373A1 (en) | 2008-05-29 |
| US20100292157A1 (en) | 2010-11-18 |
| EP2091566A4 (en) | 2011-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2670405A1 (en) | Combination treatments for alzheimer's disease and related neurodegenerative diseases | |
| KR102804813B1 (ko) | 세포 생존력을 향상시키기 위한 조성물 및 이의 사용 방법 | |
| AU2004280090B2 (en) | Dual alanyl aminopeptidase and dipeptidyl peptidase IV inhibitors for functionally influencing different cells and for treating immunological, inflammatory, neuronal and other diseases | |
| EP2123276B1 (en) | Pharmaceutical composition comprising pyrazine derivative, and method of using pyrazine derivative in combination | |
| JP2010510254A5 (cg-RX-API-DMAC7.html) | ||
| DE10348022A1 (de) | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen | |
| CN113164420B (zh) | 治疗组合物 | |
| HK1199726A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2008527002A5 (cg-RX-API-DMAC7.html) | ||
| CN1344159B (zh) | 有关血管生成疾病的治疗组合 | |
| HK1198619A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2011509286A (ja) | 精神神経系障害の治療のための、医薬組成物並びにｄ−アミノ酸及び抗酸化物を利用する方法 | |
| JP2005516911A5 (cg-RX-API-DMAC7.html) | ||
| US7291599B2 (en) | Use of inhibitors of enzymes having activities of amino peptidase N and/or dipeptidyl peptidase IV and of pharmaceutical preparations thereof for a therapy and prevention of chronical neurodegenerative diseases | |
| US12102660B2 (en) | Association of N-acetylcysteine and colistin for use in bacterial infections | |
| WO2023066216A1 (zh) | 一种包含c21甾体皂苷的药物组合物及其应用 | |
| CA3079848A1 (en) | Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use | |
| US20200323793A1 (en) | Combination therapy comprising a polyunsaturated ketone and a calcineurin inhibitor | |
| WO2017209270A1 (ja) | ２５－ヒドロキシコレステロール又はその類縁体コレステロールを有効成分として含有してなる、活性化されたｔ細胞及び／又はｂ細胞に選択的な細胞死誘導剤又は細胞死促進剤 | |
| US11608320B2 (en) | Oxazolidinone hydroxamic acid derivatives | |
| CA2678920C (en) | A medicament for treating chronic obstructive pulmonary disease | |
| WO2025134069A1 (en) | Compositions and methods for treating neurodegenerative disorders | |
| Carraro | Tetracyclines beyond the antibiotic | |
| HK40085419A (en) | Bile acid-gcpii inhibitor conjugates to treat inflammatory diseases | |
| JP2019502679A (ja) | アルツハイマー病及び／または脳アミロイド血管症の処置のための新規の化合物及び方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20131122 |
|
| FZDE | Discontinued |
Effective date: 20131122 |